Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq: MCRB) announced a conference call on November 9, 2020, at 8:30 a.m. ET to discuss Q3 2020 results and provide a business update. The SER-109 program has achieved significant clinical milestones, including Breakthrough Therapy and Orphan Drug designations from the FDA, targeting recurrent C. difficile infections. Additional programs like SER-287 and SER-401 are in various stages of clinical evaluation, with FDA designations indicating potential for innovation in microbiome therapeutics.
Seres Therapeutics (Nasdaq: MCRB) has expanded its leadership team by appointing David S. Ege as Executive Vice President and Chief Technology Officer, and Jayne M. Gansler as Executive Vice President and Chief People Officer. These appointments coincide with positive Phase 3 results for SER-109, which aims to be the first FDA-approved microbiome therapy. Previous leadership additions include Lisa von Moltke as Chief Medical Officer and Terri Young as Chief Commercial and Strategy Officer. The company is preparing for commercialization and enhancing its capabilities to support growth in the microbiome therapeutics space.
Seres Therapeutics (Nasdaq: MCRB) has announced positive Phase 3 results from the ECOSPOR III trial of SER-109, presented at the Virtual ACG Annual Meeting. The trial demonstrated a statistically significant reduction in C. difficile infection recurrence at 12 weeks post-treatment, with a 31.1% absolute risk reduction compared to placebo. The study included 182 patients and confirmed the therapy's efficacy across age groups. SER-109 aims to transform treatment for recurrent C. difficile infection, having received FDA Breakthrough Therapy and Orphan Drug designations.